GLP-1 actions beyond insulin secretion and body weight Clinically, GLP-1RAs are used to treat people with T2D and/or obesity (Figure 1), based on mechanisms described above linked to control of insulin and glucagon secretion, as well as reduction of food intake
Thats better than nothing, but it still leaves the clinician doing detective work
Morovatdar N, Poorzand H, Bondarsahebi Y, Hozhabrossadati SA, Montazeri S, Sahebkar A
It also impairs your bodys ability to metabolize fat effectively and disrupts sleep quality, both of which undermine treatment outcomes
5 Pharmacological effects of GIP, GLP-1 and their mimetics The pharmacological benefits of GIP, GLP-1, and their synthetic mimetics arise from their pleiotropic effects, encompassing at least five key functions: bolstering insulin secretion and survival of pancreatic -cells and modulating glucagon release by the pancreatic -cells in response to glycemic levels, acting on the satiety center in brain, slowing gastric emptying, regulating lipid and glucose metabolism through effects on adipose tissue and liver, and reducing systemic blood pressure
The emerging epidemic of heart failure with preserved ejection fraction
